Hong Kong-listed biopharmaceutical group Edding Genor (EDDIN G GENOR) disclosed its monthly return for July 2026, highlighting a modest contraction in free-floating shares following an active share-repurchase programme and limited equity issuance activity during the month. Key takeaways are as follows:
Share capital and structure • Authorised share capital was unchanged at 3.00 billion ordinary shares with a par value of USD 0.00002, equivalent to USD 60,000. • Total issued shares stood at 2.01 billion, flat versus June, while treasury stock rose by 2.25 million shares to 25.54 million. As a result, shares in issue excluding treasury shrank to 1.99 billion, a 0.11% month-on-month decrease. • Treasury shares now represent 1.27% of total issued shares (25.54 million out of 2.01 billion).
Repurchase activity Between 9 and 28 July, the company repurchased 2.25 million shares, all of which were held as treasury stock. The repurchases were conducted under the general mandate approved on 16 April 2026. No shares were cancelled during the period.
Equity incentive schemes • No new shares were issued and no treasury shares were transferred to satisfy employee share option exercises or restricted share unit (RSU) vesting in July. • Outstanding share options totalled 211.21 million, spread across four schemes, after the cancellation of 165,119 options under the 2025 One-off Share Option Plan. • RSU plans collectively allow for the potential issuance of 19.47 million shares, unchanged month-on-month.
Public float Despite the increased treasury position, Edding Genor confirmed compliance with the Hong Kong Main Board’s minimum public float requirement of 15% as at 31 July 2026.
Liquidity impact With no equity raised and a net 0.11% reduction in free float, the July buy-back programme marginally tightened the company’s tradable share base while preserving capital structure flexibility through sizeable unexercised option pools.
Comments